Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of THRV-1268 in Healthy Adults
NCT06507839Phase 1Completed
- Sponsor
- Thryv Therapeutics Inc.
- Start
- May 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of THRV-1268 in Atrial fibrillation (AFib) (6 arms), sponsored by Thryv Therapeutics Inc. Primary endpoint: Number of Participants with Adverse Events. Started May 2024; status: completed.
02
Drugs
THRV-1268
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06507839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06507839.